Lixte Biotechnology Holdings, Inc.Lixte Biotechnology Holdings, Inc.Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc.

No trades
See on Supercharts

Key stats

Market capitalization
‪5.15 M‬USD
Dividend yield (indicated)
Price to earnings Ratio (TTM)
Basic EPS (TTM)
Net income (FY)
Revenue (FY)
Shares float
Beta (1Y)
2.22

About Lixte Biotechnology Holdings, Inc.

CEO
Bastiaan van der Baan
Website
Headquarters
Pasadena
Founded
2005
FIGI
BBG00Y7BNLF5
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also involved in utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on May 24, 2005 and is headquartered in Pasadena, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.